4
Registered trials
1
Recruiting
4
Unique sponsors
7
Unique IMPs
3
Commercial trials
Drug classes (ATC)
B
Haematology (ATC B)
1
C
Cardiology (ATC C)
2
—
ATC code not specified
2
Mechanism of action (INN-stem analysis)
Unknown / small molecule
6 substances
Supportive / diluent
1 substance
Phase III:
1
Phase IV:
1
Phase I (Other):
1
Phase I (First in Human):
1
Phase III
1 trial-
RecruitingCytokinetics Inc. CommercialOMECAMTIV MECARBIL
Phase IV
1 trial-
EndedRigshospitalet AcademicVERICIGUAT
Phase I (Other)
1 trial-
EndedAstraZeneca AB CommercialAZD3427; DOPAMINE HYDROCHLORIDE; O15-WATER; SODIUM CHLORIDE
Phase I (First in Human)
1 trial-
Not authorisedCASC8 CommercialCASCS
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| AstraZeneca AB | Commercial | 1 | Phase I (Other) | 0 |
| Cytokinetics Inc. | Commercial | 1 | Phase III | 1 |
| CASC8 | Commercial | 1 | Phase I (First in Human) | 0 |
| Rigshospitalet | Academic | 1 | Phase IV | 0 |
New trials by year
2024
2
2025
1